Veraxa Biotech names Raju Willener as new CFO

Veraxa Biotech AG, which trades on Nasdaq under the ticker VRXA, announced the appointment of Raju Willener as Chief Financial Officer effective immediately on September 4, 2026.¹ Willener will report to Christoph Antz, the company's Chief Executive Officer and Co-Founder.¹

According to the filing, Willener will serve as the company's principal financial officer and principal accounting officer.¹

The company described his background as spanning more than three decades of international experience in investment banking, corporate finance, asset management and strategic leadership.¹ Over his career, he has taken on senior positions such as CFO, Chief Investment Officer, Country Head, and Head of Corporate Finance in the U.S., Europe, and Asia.¹

Before joining Veraxa, Willener worked at Exentis Group AG, first as Director of Corporate Development and later moving into the CFO role there in 2025, where his duties covered M&A activity, financial strategy, and other corporate functions.¹ Earlier in his career, he held senior executive and investment posts at major global financial institutions and investment firms, overseeing portfolios that at times exceeded CHF 30 billion in assets under management.¹

On his academic credentials, the filing states Willener has an MBA along with a master's degree in accounting and finance, and has a qualification in financial risk management.¹

The filing also noted a change in leadership, with Antz thanking Carl von Halem for his prior service as VERAXA's CFO.¹ The announcement was included in a Form 6-K report filed with the SEC, signed by Antz as CEO and Oliver Baumann as Chairman of the Board.